Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium Tc 99m exametazime-labeled leukocytes
- Development stage
- Unknown
- Lead developer
- GE Healthcare
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Cell Therapies
- Administration
- Intravenous
01
Overview
Technetium Tc 99m exametazime-labeled leukocytes are autologous white blood cells (primarily neutrophils) that are radiolabeled *ex vivo* with the lipophilic technetium Tc 99m exametazime complex. The exametazime ligand acts as a chelator that crosses the leukocyte cell membrane by passive diffusion and is retained intracellularly via glutathione-mediated conversion into a hydrophilic complex. Once reinjected intravenously, these labeled leukocytes migrate via chemotaxis and localize to active sites of infection or inflammation. This diagnostic radiopharmaceutical is used in scintigraphy and single-photon emission computed tomography (SPECT) imaging to localize intra-abdominal infections and inflammatory bowel disease in both adult and pediatric patients.
- Brand names
- CeretecDrax Exametazime
- Other names
- 99mTc-HMPAO-labeled leukocytes99mTc-HMPAO-leucocytes99mTc-exametazime-labeled leukocytesTc 99m exametazime-labeled leukocytesTc99m exametazime-labeled leukocytesTc-99m exametazime-labeled leukocytestechnetium Tc 99m exametazime labeled leukocytestechnetium Tc 99m exametazime-labeled white blood cellstechnetium Tc-99m exametazime-labeled leukocytestechnetium-99m HMPAO labeled leukocytestechnetium99m HMPAO labeled leukocytestechnetium 99m HMPAO labeled leukocytestechnetium-99m hexamethylpropyleneamine oxime labeled leukocytestechnetium99m hexamethylpropyleneamine oxime labeled leukocytestechnetium 99m hexamethylpropyleneamine oxime labeled leukocytes
Beyond the preview
Go deeper on technetium Tc 99m exametazime-labeled leukocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium Tc 99m exametazime-labeled leukocytes.